News | March 29, 2023
Thalassemics India celebrates 35 years of service in Thalassemia
The event witnessed a historic journey of Thalassemics India gracing the theme “LAKSH”
The event witnessed a historic journey of Thalassemics India gracing the theme “LAKSH”
A First of its Kind Initiative in Mahbubnagar District for Medical Officers, ANM, Anganwadi workers for prevention of Thalassemia and Sickle Cell anemia as part of Antenatal screening of pregnant women project
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Thalassemia and Sickle Cell Society (TSCS) always stands forefront in providing blood transfusion free of cost for Thalassemia Blood disorders patients
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)